Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma
Lenvatinib potentiates RT and anti-PD-L1 therapy in LUAD through dual immune-vascular modulation, supporting the clinical translation of this triple-combination strategy.
Authors
- X D Zhang
- Jianming Huang
- Cheng Tang (ORCID: https://orcid.org/0000-0003-4208-1024)
- L. Li
- Ling Xiao (ORCID: https://orcid.org/0000-0003-0893-1777)
- Jiahua Lyu
- Shichuan Zhang
- Tao Li
- Yudi Liu
- Xinyu Nie
Institutions
- People's Hospital of Kaizhou District (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/15384047.2025.2610526
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00